Biotech Values

[walldiver]

DNDN Read Me First

Updated with three most recent webcasts (10/31 conf call on Provenge 9902A trial results at ECCO, 11/4 conf call on Q3 financial results, 11/7 webcast at Rodman & Renshaw conference)
http://investor.dendreon.com/medialist.cfm

UBS 9/27/05 Conference Call Transcript and Breakout Session Notes
http://www.investorshub.com/boards/read_msg.asp?message_id=7922336

Dr. Eric Small presentation of 9901 trial results at May 2005 ASCO Conference
http://tinyurl.com/e2ceu

Conf call transcript about 9902A survival data
http://tinyurl.com/8e74r

DNDN newsroom for investors
http://investor.dendreon.com/newsroom/

Discussion thread of some clinical trial summations on competitive hormone-refractory prostate cancer treatments (courtesy of Rancherho)...thread continues with surrogate endpoint discussion and links
http://tinyurl.com/8syxr
http://tinyurl.com/99kfb
http://tinyurl.com/armgl
http://tinyurl.com/bnscm
http://tinyurl.com/7ozey
http://tinyurl.com/89h5p
http://tinyurl.com/ey5tf
http://tinyurl.com/99bdm

Feb/Mar 2005 webcasts below
Invest Northwest webcast and annotations:
#msg-6163862

4Q04 quarterly CC (3/15/05):
http://investor.dendreon.com/medialist.cfm
Accompanying PR: #msg-5743992

Well Fargo fireside chat with CEO Mitch Gold (3/2/05):
http://investor.dendreon.com/medialist.cfm

DNDN’s 9901 data-release CC (2/22/05):
http://investor.dendreon.com/medialist.cfm

ASCO Prostate Cancer presentation Dr. Eric Small 2/19/05:
http://tinyurl.com/4b7to

Provenge potential market msg board posts
http://tinyurl.com/7dwm6
http://tinyurl.com/3k857

FDA Prostate Cancer Workshop 6/04 (change to Transcript2.pdf and 3.pdf for continuation)
http://www.fda.gov/cder/drug/cancer_endpoints/ProstateTranscript1.pdf

9901 trial Gleason score breakdown (we now know that 4 out of 5 surviving placebo arm patients crossed over to receive salvage Provenge after progression)
http://tinyurl.com/5v6xy

ASCO Prostate message-board musings (2/05)
http://tinyurl.com/5hykx
http://tinyurl.com/4ssxf
http://tinyurl.com/4njwt

Biotech Monthly has the most comprehensive background info for Dendreon, far more than any brokerage house. The Nov 2004 issue would be available for a single-issue purchase, approx 40 pages are devoted to Dendreon. Price for single issue is in the $100 range. The issue covers the Provenge mechanism of action, trial history, and pipeline.
http://www.biotechMonthly.com/archive_2004.htm

The ever-changing short-seller arguments (inspired by David Miller)
http://www.investorshub.com/boards/read_msg.asp?message_id=5875436

DNDN Insider Transactions
http://finance.yahoo.com/q/it?s=DNDN

Basic facts about prostate cancer
http://www.cancer.gov/cancertopics/types/prostate
http://www.acor.org/cnet/glossary/45696.html